Clinical Trials Logo

Clinical Trial Summary

This is an open-label, single-arm, prospective phase 2 study, evaluating the efficacy and safety of tislelizumab combined with sitravatinib as maintenance therapy following tislelizumab and chemotherapy for treatment naïve extensive stage small cell lung cancer.


Clinical Trial Description

The study included screening period, treatment period (including induction and maintenance), safety follow-up and survival follow-up periods. Induction treatment will be administered on a Q3W cycle for 4 cycles. Following induction treatment, patients who have received 4 cycles of tislelizumab and platinum-based chemotherapy and meet the following criteria will enter a maintenance treatment phase with tislelizumab and sitravatinib: Patients have an ongoing response per RECIST v1.1 criteria of SD or better assessed by the investigator according to RECIST v1.1(Patients will be eligible to enter maintenance phase if chemotherapy interruption due to toxicity, but at least 3 cycles of tislelizumab combined with chemotherapy are completed and assessed as CR, PR or SD according to RECISTv1.1 criteria). Excluded patients with central cavitary ES-SCLC, or tumor invading or adjacent to large vessels as shown by imaging, and likely to invade large vessels and cause fatal bleeding assessed by the investigator. During the maintenance treatment period prophylactic cranial irradiation (PCI) is permitted as per local standard of care. Treatment may continue until 1) disease progression as assessed by the investigator per RECIST v1.1, 2) loss of clinical benefit as assessed by the investigator, 3) unacceptable toxicity, or 4) withdrawal of informed consent, whichever occurs first, 5) study treatment duration reached 2 years (including induction and maintenance period). Per investigator's discretion, patients who may continue to benefit from study treatment after progressive disease must meet the following criteria in order to be treated and documented in the study records: Absence of symptoms and signs indicating clinically significant progression of disease and absence of worsening of laboratory values indicating disease progression. Stable ECOG performance status ≤ 1 Absence of rapid progression of disease or of progressive tumor at critical anatomical sites (eg,cord compression) that requires urgent alternative medical intervention Investigators must obtain written informed consent for treatment beyond radiologic disease. Study treatment will be administered for up to 2 years (including induction and mantenance period). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05228496
Study type Interventional
Source Zhejiang Cancer Hospital
Contact
Status Active, not recruiting
Phase Phase 2
Start date March 17, 2022
Completion date June 1, 2025

See also
  Status Clinical Trial Phase
Completed NCT00046111 - A Bioequivalence Study of Two Oral Formulations of Topotecan in Patients With Advanced Solid Tumors Phase 1
Enrolling by invitation NCT06293833 - Implementation of Lung Cancer Screening in the First Line Zone of ZORA (Flanders), Using a Low Dose CT-scan N/A
Completed NCT00259935 - A Study To Determine If Two Different Versions Of Topotecan Have The Same Potency In Patients With Advanced Solid Tumors Phase 1
Completed NCT01037023 - Regulatory Hycamtin(Oral) PMS N/A
Active, not recruiting NCT04986670 - NutriCare Plus a Medically Tailored Meal Intervention Among Patients With Lung Cancer N/A
Completed NCT00997061 - SCOT Registry: Small Cell Lung Cancer Treatment and Outcome N/A
Completed NCT00276276 - Active Symptom Control Alone Or In Combination With Oral Topotecan In Patients With Relapsed Resistant Small Cell Lung Cancer Phase 3
Not yet recruiting NCT05320458 - Pulmonary Rehabılıtatıon Wıth Non-Small Lung Cancer N/A
Completed NCT00316186 - First-line Treatment Of Subjects With Extensive Disease Small Cell Lung Cancer With Weekly Hycamtin And Paraplatin Phase 2
Not yet recruiting NCT04440800 - Feasibility of Wearable Activity Trackers for Detection of TOXicity in People Receiving Systemic Anticancer Treatment
Completed NCT00698516 - Study of Oral Topotecan With Bevacizumab for Recurrent Small Cell Lung Cancer Phase 2
Terminated NCT03499678 - Lung Cancer Screening Using DNA Methylation Changes in Circulated Tumor and PBMC DNA
Terminated NCT01313663 - A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) Population Phase 2
Active, not recruiting NCT04660929 - CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors Phase 1
Completed NCT00043862 - The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC) Phase 2
Completed NCT00320359 - Topotecan Plus Cisplatin Versus Etoposide Plus Cisplatin In 1st Line Extensive Disease Small Cell Lung Cancer Phase 3
Recruiting NCT06228326 - A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs Phase 1
Completed NCT04314895 - Trial of NanoPac Intratumoral Injection in Lung Cancer Phase 2